Barclays’s Decibel Therapeutics, Inc. Common Stock DBTX Stock Holding History

Barclays’s Portfolio DBTX Stock Details DBTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-10,855	Closed	-$41.8K	–	4767
2023 Q2	$41.8K	Hold	10,855	–	–	﹤0.01%	3912
2023 Q1	$32.8K	Sell	10,855 -227,822	-95%	-$787K	﹤0.01%	4545
2022 Q4	$489K	Sell	238,677 -800	-0.3%	-$2.44K	﹤0.01%	3326
2022 Q3	$829K	Hold	239,477	–	–	﹤0.01%	2361
2022 Q2	$1.01M	Sell	239,477 -860	-0.4%	-$2.03K	﹤0.01%	2337
2022 Q1	$731K	Buy	+240,337	New	+$921K	﹤0.01%	2634

Other funds holding DBTX

ACA

Atlas Capital Advisors Jackson, Wyoming $914M AUM

Barclays's DBTX Position: Q3 2023 in Review

Barclays sold out of Decibel Therapeutics, Inc. Common Stock (DBTX) in Q3 2023, closing a stake of 10,855 shares — an estimated $41.8K sold.

Barclays first reported a position in DBTX in Q1 2022 and held it in 6 quarters. The position peaked at $1.01M in Q2 2022. 1 fund tracked by Wall St. Rank holds DBTX as of Q3 2023.

Barclays reported no remaining Decibel Therapeutics, Inc. Common Stock position as of Q3 2023 after selling out during the quarter.
Barclays sold 10,855 Decibel Therapeutics, Inc. Common Stock shares in Q3 2023, an estimated $41.8K.
Barclays first reported a position in Decibel Therapeutics, Inc. Common Stock in Q1 2022 and held it in 6 quarters.
Barclays's Decibel Therapeutics, Inc. Common Stock position peaked at $1.01M in Q2 2022.
1 fund tracked by Wall St. Rank held Decibel Therapeutics, Inc. Common Stock as of Q3 2023.

Based on Barclays's 13F filing for Q3 2023, filed 7 Nov 2023.